Emergent Biosolutions Inc (NYSE: EBS) has seen a rise in its stock price by 3.35 in relation to its previous close of 9.25. However, the company has experienced a 17.30% gain in its stock price over the last five trading sessions. fool.com reported 2024-12-30 that An analyst initiated coverage of Emergent BioSolutions (EBS 11.85%) stock as the last trading week of 2024 kicked off, and investors reacted quite positively to the move. On the news, they piled into the stock, ultimately sending it to a nearly 12% gain on the day.
Is It Worth Investing in Emergent Biosolutions Inc (NYSE: EBS) Right Now?
Moreover, the 36-month beta value for EBS is 1.61. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EBS is 52.07M and currently, short sellers hold a 13.32% of that float. On January 01, 2025, EBS’s average trading volume was 1.32M shares.
EBS’s Market Performance
EBS stock saw a decrease of 17.30% in the past week, with a monthly decline of -5.53% and a quarterly a decrease of 12.87%. The volatility ratio for the week is 7.36%, and the volatility levels for the last 30 days are 6.19% for Emergent Biosolutions Inc (EBS). The simple moving average for the last 20 days is 9.94% for EBS stock, with a simple moving average of 30.73% for the last 200 days.
Analysts’ Opinion of EBS
Many brokerage firms have already submitted their reports for EBS stocks, with H.C. Wainwright repeating the rating for EBS by listing it as a “Buy.” The predicted price for EBS in the upcoming period, according to H.C. Wainwright is $15 based on the research report published on December 30, 2024 of the previous year 2024.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see EBS reach a price target of $16. The rating they have provided for EBS stocks is “Buy” according to the report published on August 22nd, 2024.
The Benchmark Company gave a rating of “Buy” to EBS, setting the target price at $5 in the report published on March 07th of the previous year.
EBS Trading at 3.70% from the 50-Day Moving Average
After a stumble in the market that brought EBS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.69% of loss for the given period.
Volatility was left at 6.19%, however, over the last 30 days, the volatility rate increased by 7.36%, as shares sank -2.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.25% upper at present.
During the last 5 trading sessions, EBS rose by +17.30%, which changed the moving average for the period of 200-days by +290.20% in comparison to the 20-day moving average, which settled at $8.70. In addition, Emergent Biosolutions Inc saw 298.33% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EBS starting from DeGolyer Donald W, who sale 25,000 shares at the price of $10.91 back on Nov 12 ’24. After this action, DeGolyer Donald W now owns 111,100 shares of Emergent Biosolutions Inc, valued at $272,750 using the latest closing price.
White Marvin L, the Director of Emergent Biosolutions Inc, sale 14,287 shares at $11.97 during a trade that took place back on Nov 11 ’24, which means that White Marvin L is holding 54,092 shares at $171,015 based on the most recent closing price.
Stock Fundamentals for EBS
Current profitability levels for the company are sitting at:
- -0.09 for the present operating margin
- 0.29 for the gross margin
The net margin for Emergent Biosolutions Inc stands at -0.19. The total capital return value is set at -0.08. Equity return is now at value -34.64, with -12.39 for asset returns.
Based on Emergent Biosolutions Inc (EBS), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 213.38. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -1.23.
Currently, EBITDA for the company is -505.3 million with net debt to EBITDA at -6.29. When we switch over and look at the enterprise to sales, we see a ratio of 0.33. The receivables turnover for the company is 9.28for trailing twelve months and the total asset turnover is 0.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.88.
Conclusion
To wrap up, the performance of Emergent Biosolutions Inc (EBS) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
